Success Metrics

Clinical Success Rate
40.0%

Based on 2 completed trials

Completion Rate
40%(2/5)
Active Trials
0(0%)
Results Posted
100%(2 trials)
Terminated
3(60%)

Phase Distribution

Ph phase_3
5
100%

Phase Distribution

0

Early Stage

0

Mid Stage

5

Late Stage

Phase Distribution5 total trials
Phase 3Large-scale testing
5(100.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

40.0%

2 of 5 finished

Non-Completion Rate

60.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(2)
Terminated(3)

Detailed Status

Terminated3
Completed2

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
40.0%
Most Advanced
Phase 3

Trials by Phase

Phase 35 (100.0%)

Trials by Status

completed240%
terminated360%

Recent Activity

0 active trials
Showing 5 of 5
terminatedphase_3

A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD)

NCT05518149
terminatedphase_3

A Study of Aticaprant Plus an Antidepressant to Prevent Return of Depression Symptoms in Participants With Major Depressive Disorder Who Experience a Loss of Interest and Pleasure

NCT06635135
terminatedphase_3

A Study of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and Long-term Extension Treatment With Aticaprant

NCT06514742
completedphase_3

A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy

NCT05550532
completedphase_3

A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy

NCT05455684

Clinical Trials (5)

Showing 5 of 5 trials
NCT05518149Phase 3

A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD)

Terminated
NCT06635135Phase 3

A Study of Aticaprant Plus an Antidepressant to Prevent Return of Depression Symptoms in Participants With Major Depressive Disorder Who Experience a Loss of Interest and Pleasure

Terminated
NCT06514742Phase 3

A Study of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and Long-term Extension Treatment With Aticaprant

Terminated
NCT05550532Phase 3

A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy

Completed
NCT05455684Phase 3

A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5